BillionToOne, Inc. BLLN

What this company does

BillionToOne commercializes its UNITY and Northstar tests in the United States through a direct sales force that targets physicians in the prenatal and oncology markets, respectively. As of December 31, 2025, the company had 713 employees, all of them full-time. Its laboratories in Menlo Park and Union City, California, are CLIA certified. As of December 31, 2025, its sales organization included 231 sales representatives, with 177 assigned to prenatal and 54 to oncology. More than 90% of its 2025 revenue came from reimbursement of its prenatal and oncology tests in the United States. UNITY is a prenatal test that uses cell-free DNA to provide fetal risk assessment for recessive conditions such as sickle cell disease and cystic fibrosis without requiring a paternal sample or invasive procedures such as amniocentesis. Northstar Select is a liquid biopsy test that provides insight into appropriate therapies for patients with stage III or IV cancer. Northstar Response is a tissue-free, pan-cancer liquid biopsy test that measures thousands of genomic loci methylated in cancer to indicate changes in a patient's response to therapy.

Written from the business description in BillionToOne, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 11 March 2026. Every sentence was checked against that document before publication.